Clemizole (EPX-100)

Small molecule

Phase 3underway

Evidence outlook · registrational

Epilepsy: registrational readout pending

No completed mid-stage readout is on record. ClinicalTrials.gov estimates the registrational readout at 2027-04; company guidance (Harmony Biosciences, stated 2026-08-04): topline data expected 1H 2027.

Also in development:Dravet Syndrome · Phase 3Lennox-Gastaut Syndrome · Phase 3

Company guidance: topline data expected 1H 2027 (NCT05066217; Harmony Biosciences, 4 Aug 2026). “Topline data expected in 1H 2027 and anticipated PDUFA dates in 2028” Source ↗

Company guidance: topline data expected 1H 2027 (NCT04462770; Harmony Biosciences, 4 Aug 2026). “Topline data expected in 1H 2027 and anticipated PDUFA dates in 2028” Source ↗

Company guidance: regulatory decision expected in 2028 (Harmony Biosciences, 4 Aug 2026). “Topline data expected in 1H 2027 and anticipated PDUFA dates in 2028” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Dravet Syndrome
Lennox-Gastaut Syndrome
Phase 2 (1)
Other / comorbidity
NCT03069508 · Eiger Group International, Inc.
2017-02-13 – 2018-01-31 · Hepatocellular Carcinoma
What this study did
Phase 1 (4)
Dravet Syndrome
NCT04069689 · Epygenix
2019-08-29 – 2019-11-27 · Dravet Syndrome
What this study did
Other / comorbidity
NCT07879170 · Epygenix
2026-08-05 – 2026-12-30 · Healthy Participants
What this study did
NCT07824193 · Epygenix
2025-01-15 – 2025-04-03 · Drug Drug Interaction
What this study did
NCT00945880 · Eiger BioPharmaceuticals
2009-07 – 2010-08 · Hepatitis C
What this study did

Competitive landscape

This drug's own stage for Dravet Syndrome: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Clemizole (EPX-100): this drugPhase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
NCT02926898: Change in monthly convulsive seizure frequency over titration plus maintenance, fenfluramine 0.4 mg/kg/day (n=43) vs placebo (n=44), in Dravet syndrome on stiripentol-inclusive regimens: 54.0% greater reduction with fenfluramine (95% CI 35.6% to 67.2%); ANCOVA p<0.001 (CT.gov posted analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
ZorevunersenPhase 3RNA / oligonucleotideSCN1A mRNAWeak signalNo reviewed efficacy summary in this indication
Cannabidiol (Kanbis)
Phase 2(overall)
Small moleculecannabinoidnot yet gradedNo reviewed efficacy summary in this indication
Huperzine A (SPN-817)
Phase 2(overall)
Small moleculeAcetylcholinesterasenot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Clemizole (EPX-100) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Healthy ParticipantsRecruiting
Est. primary completion 2026-12-30 · NCT07879170 · CT.gov ↗
What to watch
2027 (1)
April 2027 (1)
Phase 3EpilepsyRecruiting
Est. primary completion 2027-04 · NCT04462770 · CT.gov ↗

Company guidance: topline data expected 1H 2027 (Harmony Biosciences, 4 Aug 2026). “Topline data expected in 1H 2027 and anticipated PDUFA dates in 2028” Source ↗

What to watch

See the full readout calendar ↗